Eris Lifesciences: Buy for an potential upside of 33% over the next 12 months

Ventura Securities | April 13, 2018, 1:03 p.m.

We initiate coverage on Eris as a BUY with a price target of Rs 1,060, representing a potential upside of 33% over the next 12 months. We arrived at the price target by applying 30 times PE multiple to FY20E business earnings and adding Rs. 22 cash per share.



blog comments powered by Disqus